The institution is rethinking what a museum can be by prioritizing experimentation, artistic production and public engagement ...
Accent Therapeutics launched a Phase I/II clinical trial last year to begin testing a small molecule inhibitor of KIF18A in ovarian cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results